Special Issue

Medical Applications of Bioactive Peptides

Message from the Guest Editors

Bioactive peptides have sparked substantial interest due to their potency, selectivity, and low toxicity and are now considered an emerging therapeutic option. Chemical modifications, along with the use of delivery platforms, have contributed to address their most critical pharmacokinetic issues and increased their applications in medical fields. Therefore, this Special Issue will be devoted to topics and advances in the design, synthesis, and pharmacological investigations of peptide-based molecules aimed at challenging pathological conditions such as cancer, infectious diseases, inflammation, diabetes, neurodegenerative, and cardiovascular diseases. The identification and characterization of novel bioactive peptides, the elucidation of their mechanism of action and the use of chemical strategies to improve their drug-like properties are within the scopes. As well as the use of bioactive peptides as molecular probes and diagnostic tools, and their targeted delivery are also welcome.

Guest Editors

Dr. Francesco Merlino

Dr. Rosa Bellavita

Prof. Dr. Fernando Albericio

Deadline for manuscript submissions

closed (31 May 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/132860

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).